[1]袁静雅,彭慧芳,张颖裕,等.细胞焦亡与糖尿病血管并发症关系的研究进展[J].国际内分泌代谢杂志,2022,42(03):207-210.[doi:10.3760/cma.j.cn121383-20210206-02016]
　Yuan Jingya,Peng Huifang,Zhang Yingyu,et al.Association between pyroptosis and vascular complications of diabetes[J].International Journal of Endocrinology and Metabolism,2022,42(03):207-210.[doi:10.3760/cma.j.cn121383-20210206-02016]
点击复制

细胞焦亡与糖尿病血管并发症关系的研究进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
42
期数:
2022年03期
页码:
207-210
栏目:
综述
出版日期:
2022-05-20

文章信息/Info

Title:
Association between pyroptosis and vascular complications of diabetes
作者:
袁静雅; 彭慧芳; 张颖裕; 雷方; 姜宏卫
河南科技大学临床医学院、河南科技大学第一附属医院内分泌代谢科、国家代谢性疾病临床医学研究中心洛阳分中心 471003
Author(s):
Yuan Jingya;  Peng Huifang;  Zhang Yingyu;  Lei Fang;  Jiang Hongwei.
College of Clinical Medicine of Henan University of Science and Technology, Department of Metabolism and Endocrinology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang sub-center of National Clinical Research Center for Metabolic Diseases, Luoyang 471003, China
关键词:
细胞焦亡;  炎性小体;  糖尿病血管并发症
Keywords:
Pyroptosis;  Inflammasome;  Diabetic vascular complications
DOI:
10.3760/cma.j.cn121383-20210206-02016
摘要:
糖尿病血管病变是主要的糖尿病慢性并发症,是导致患者生活质量下降和预期寿命缩短的最主要原因。细胞质内模式识别受体(PRRs)可感受多种刺激形成炎性小体,激活焦亡通路,加重糖尿病患者代谢紊乱,促进糖尿病血管并发症的发生发展。本文浅谈细胞焦亡对不同糖尿病血管并发症的促进作用,以及抑制焦亡通路可能为糖尿病血管并发症的早期诊治提供新的思路。
Abstract:
Diabetic vascular complications are the main chronic complications of diabetes, which is the main reason for the loss of quality of life and the shortening of life expectancy in diabetic patients. Pattern recognition receptors(PRRs)can sense stimulation to form inflammasomes, which activates the pyroptosis pathway, aggravates the metabolic disorder of diabetic patients, and promotes the occurrence and development of diabetic vascular complications. This article systematically reviews the promoting effect of pyroptosis on the vascular complications of diabetes, and inhibiting the pyroptosis pathway may provide new ideas for the early diagnosis and treatment of diabetic vascular complications.

参考文献/References:

[1] Lunder M,Janic' M,abovicˇ M.Prevention of vascular complications in diabetes mellitus patients: focus on the arterial wall[J].Curr Vasc Pharmacol,2019,17(1):6-15.DOI:10.2174/1570161116666180206113755.
[2] Jorgensen I,Miao EA.Pyroptotic cell death defends against intracellular pathogens[J].ImImmunol Rev,2015,265(1),130-142.DOI:10.1111/imr.12287.
[3] Broz P,Pelegrín P,Shao F.The gasdermins,a protein family executing cell death and inflammation[J].Nat Rev Immunol,2020,20(3):143-157.DOI:10.1038/s41577-019-0228-2.
[4] Shi J,Gao W,Shao F.Pyroptosis:Gasdermin-Mediated Programmed Necrotic Cell Death[J].Trends Biochem Sci,2017,42(4):245-254.DOI:10.1016/j.tibs.2016.10.004.
[5] Kiviniemi AM,Lepojärvi ES,Tulppo MP,et al.Prediabetes and risk for cardiac death among patients with coronary artery disease:the ARTEMIS study[J].Diabetes Care,2019,42(7):1319-1325.DOI:10.2337/dc18-2549.
[6] Leng W,Ouyang X,Lei X,et al.The SGLT-2 Inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE+ mice[J].Mediators Inflamm,2016,2016:6305735.DOI:10.1155/2016/6305735.
[7] Wan Z,Fan Y,Liu X,et al.NLRP3 inflammasome promotes diabetes-induced endothelial inflammation and atherosclerosis[J].Diabetes Metab Syndr Obes,2019,12:1931-1942.DOI:10.2147/DMSO.S222053.
[8] Hang L,Peng Y,Xiang R,et al.Ox-LDL causes endothelial cell Injury through ASK1/NLRP3-Mediated inflammasome activation via endoplasmic reticulum stress[J].Drug Des Devel Ther,2020,14:731-744.DOI:10.2147/DDDT.S231916.
[9] Castro-Alves VC,Shiga TM,Nascimento JROD.Polysaccharides from chayote enhance lipid efflux and regulate NLRP3 inflammasome priming in macrophage-like THP-1 cells exposed to cholesterol crystals[J].Int J Biol Macromol,2019,127:502-510.DOI:10.1016/j.ijbiomac.2019.01.048.
[10] Le NT,Sandhu UG,Quintana-Quezada RA,et al.Flow signaling and atherosclerosis[J].Cell Mol Life Sci,2017,74(10):1835-1858.DOI:10.1007/s00018-016-2442-4.
[11] Lee J,Wan J,Lee L,et al.Study of the NLRP3 inflammasome component genes and downstream cytokines in patients with type 2 diabetes mellitus with carotid atherosclerosis[J].Lipids Health Dis,2017,16(1):217.DOI:10.1186/s12944-017-0595-2.
[12] McDowell RE,Barabas P,Augustine J,et al.Müller glial dysfunction during diabetic retinopathy in rats is reduced by the acrolein-scavenging drug,2-hydrazino-4,6-dimethylpyrimidine[J].Diabetologia,2018,61(12):2654-2667.DOI:10.1007/s00125-018-4707-y.
[13] Du J,Wang Y,Tu Y,et al.A prodrug of epigallocatechin-3-gallate alleviates high glucose-induced pro-angiogenic factor production by inhibiting the ROS/TXNIP/NLRP3 inflammasome axis in retinal Müller cells[J].Exp Eye Res,2020,196:108065.DOI:10.1016/j.exer.2020.108065.
[14] Singh LP,Devi TS,Yumnamcha T.The Role of Txnip in mitophagy dysregulation and inflammasome activation in diabetic retinopathy:a New perspective[J].JOJ Ophthalmol,2017,4(4).DOI:10.19080/jojo.2017.04.555643.
[15] Chaurasia SS,Lim RR,Parikh BH,et al.The NLRP3 inflammasome may contribute to pathologic neovascularization in the advanced stages of diabetic retinopathy[J].Sci Rep,2018,8(1):2847.DOI:10.1038/s41598-018-21198-z.
[16] Zhang Y,Lv X,Hu Z,et al.Protection of Mcc950 against high-glucose-induced human retinal endothelial cell dysfunction[J].Cell Death Dis,2017,8(7):e2941.DOI:10.1038/cddis.2017.308.
[17] Loukovaara S,Piippo N,Kinnunen K,et al.NLRP3 inflammasome activation is associated with proliferative diabetic retinopathy[J].Acta Ophthalmol,2017,95(8):803-808.DOI:10.1111/aos.13427.
[18] Shahzad K,Bock F,Dong W,et al.Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy[J].Kidney Int,2015,87(1):74-84.DOI:10.1038/ki.2014.271.
[19] Fang L,Xie D,Wu X,et al.Involvement of endoplasmic reticulum stress in albuminuria induced inflammasome activation in renal proximal tubular cells[J].PLoS One,2013,8(8):e72344.DOI:10.1371/journal.pone.0072344.
[20] Gao P,He FF,Tang H,et al.NADPH oxidase-induced NALP3 inflammasome activation is driven by thioredoxin-interacting protein which contributes to podocyte injury in hyperglycemia[J].J Diabetes Res,2015,2015:504761.DOI:10.1155/2015/504761.
[21] Hong J,Li G,Zhang Q,et al.D-Ribose Induces podocyte NLRP3 inflammasome activation and glomerular injury via AGEs/RAGE pathway[J].Front Cell Dev Biol,2019,7:259.DOI:10.3389/fcell.2019.00259.
[22] Liu Q,Zhang F,Zhang X,et al.Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation[J].Mol Cell Biochem,2018,445(1-2):105-115.DOI:10.1007/s11010-017-3256-x.
[23] Wang Y,Yu B,Wang L,et al.Pioglitazone ameliorates glomerular NLRP3 inflammasome activation in apolipoprotein E knockout mice with diabetes mellitus[J].PloS One,2017,12(7):e0181248.DOI:10.1371/journal.pone.0181248.
[24] Jiang Y,Du H,Liu X,et al.Artemisinin alleviates atherosclerotic lesion by reducing macrophage inflammation via regulation of AMPK/NF-κB/NLRP3 inflammasomes pathway[J].J Drug Target,2020,28(1):70-79.DOI:10.1080/1061186X.2019.1616296.
[25] Li R,Chen L,Yao GM,et al.Effects of quercetin on diabetic retinopathy and its association with NLRP3 inflammasome and autophagy[J].Int J Ophthalmol,2021,14(1):42-49.DOI:10.18240/ijo.2021.01.06.
[26] Wang C,Hou XX,Rui HL,et al.Artificially cultivated Ophiocordyceps sinensis artificially cultivated alleviates diabetic nephropathy and Its podocyte injury via inhibiting P2X7R expression and NLRP3 inflammasome activation[J].J Diabetes Res,2018,2018:1390418.DOI:10.1155/2018/1390418.
[27] Lainka E,Baehr M,Raszka B,et al.Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis-data from the German AID-registry[J].Pediatr Rheumatol Online J,2021,19(1):38.DOI:10.1186/s12969-021-00510-8.
[28] Han J,Zuo Z,Shi X,et al.Hirudin ameliorates diabetic nephropathy by inhibiting Gsdmd-mediated pyroptosis[J].Cell Biol Toxicol,2021.DOI:10.1007/s10565-021-09622-z.Epub ahead of print.

相似文献/References:

[1]张瑜,姚佳佳,黄莉吉,等.细胞焦亡在糖尿病肾病发病机制中作用的研究进展[J].国际内分泌代谢杂志,2022,42(02):150.[doi:10.3760/cma.j.cn121383-20201123-11050]
　Zhang Yu,Yao Jiajia,Huang Liji,et al.Role of pyroptosis in the pathogenesis of diabetic kidney disease[J].International Journal of Endocrinology and Metabolism,2022,42(03):150.[doi:10.3760/cma.j.cn121383-20201123-11050]

备注/Memo

备注/Memo:
通信作者:姜宏卫,Email:jianghw@haust.edu.cn
更新日期/Last Update: 2022-05-10